Award
National Cancer Institute 1R01CA302934-01A1
Defining biomarkers and overcoming resistance to DLL3-targeting immune therapies in lung cancer
Recipient
University of Texas MD Anderson Cancer Center
Award Amount
$671,740.00
Ceiling
$671,740.00
Awarded
July 23, 2026
Identifier
1R01CA302934-01A1
Award to University of Texas MD Anderson Cancer Center for research on biomarkers and resistance to DLL3-targeting immune therapies in lung cancer, with a focus on reducing animal testing.
Description
Focus on biomarkers, immune response, and resistance mechanisms in small cell lung cancer (SCLC) related to DLL3-targeting therapies. Emphasis on reducing animal testing through in vitro and computational studies.